TMDIF vs. PDEX, RCEL, BSGM, KRMD, PTHL, LAKE, LUCD, INFU, OBIO, and LUNG
Should you be buying Titan Medical stock or one of its competitors? The main competitors of Titan Medical include Pro-Dex (PDEX), Avita Medical (RCEL), Biosig Technologies (BSGM), KORU Medical Systems (KRMD), Pheton (PTHL), Lakeland Industries (LAKE), Lucid Diagnostics (LUCD), InfuSystem (INFU), Orchestra BioMed (OBIO), and Pulmonx (LUNG). These companies are all part of the "medical equipment" industry.
Titan Medical vs. Its Competitors
Pro-Dex (NASDAQ:PDEX) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
In the previous week, Pro-Dex had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Pro-Dex and 0 mentions for Titan Medical. Pro-Dex's average media sentiment score of 1.87 beat Titan Medical's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media.
Titan Medical has lower revenue, but higher earnings than Pro-Dex. Titan Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Pro-Dex currently has a consensus price target of $56.00, suggesting a potential upside of 12.40%. Given Pro-Dex's stronger consensus rating and higher possible upside, equities analysts plainly believe Pro-Dex is more favorable than Titan Medical.
Pro-Dex has a net margin of 14.61% compared to Titan Medical's net margin of 0.00%. Pro-Dex's return on equity of 29.08% beat Titan Medical's return on equity.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 47.5% of Pro-Dex shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Pro-Dex has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Summary
Pro-Dex beats Titan Medical on 14 of the 16 factors compared between the two stocks.
Get Titan Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDIF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
TMDIF vs. The Competition
Titan Medical Competitors List
Related Companies and Tools
This page (NASDAQ:TMDIF) was last updated on 7/25/2025 by MarketBeat.com Staff